Relay Therapeutics Prices $275M Public Offering at $12.00/Share, Upsized from Initial $175M Plan
RLAY has more than doubled off its 52-week low of $2.75 on elevated volume (2.0× avg).
Summary
Relay Therapeutics announced the pricing of an underwritten public offering of 22,916,667 shares of its common stock at $12.00 per share, expecting gross proceeds of approximately $275 million. This offering includes an option for underwriters to purchase additional shares. This significantly upsizes the previously announced proposed offering of $175 million on May 19, which followed positive mid-stage trial results for its experimental treatment, zovegalisib. While the substantial capital raise bolsters the company's cash reserves and extends its financial runway, crucial for a clinical-stage biotech, the offering is priced at a discount to the current market price, indicating immediate dilution for existing shareholders. Traders will closely monitor the closing of the offering and its impact on the stock price, as well as the strategic deployment of these funds for pipeline advancement.
At the time of this announcement, RLAY was trading at $13.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5B. The 52-week trading range was $2.75 to $17.32. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.